Maria Anna Siciliano Stefano Dastoli Maria d'Apolito Nicoletta Staropoli Pierfrancesco Tassone Pierosandro Tagliaferri Vito Barbieri
10.3389/fonc.2020.579445
Front Oncol
2020 Oct 14;10:579445.
apremilast pembrolizumab checkpoint inhibitors cutaneous immune-related adverse events immune-related adverse events immunotherapy melanoma psoriasis
CC BY
https://pubmed.ncbi.nlm.nih.gov/33163407/
Case Reports
PMC7591674
33163407
Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report
2020